Aktienanalyse zu Microbot Medical Inc (MBOT)MBOTMicrobot Medical Inc

Microbot Medical Inc. is a pre-commercial stage medical technology company. It has developed the single-use, fully disposable endovascular robotic system, which aims to eliminate traditional barriers to accessing advanced robotic systems. It specializes in the research, design and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. Using its LIBERTY technological platform, it is developing a fully disposable robot for various endovascular interventional procedures. The LIBERTY Endovascular Robotic Surgical System is designed to maneuver guidewires and over-the-wire devices (such as microcatheters) within the body’s vasculature. It eliminates the need for extensive capital equipment requiring dedicated Cath-lab rooms as well as dedicated staff. Its addressable markets for the LIBERTY Endovascular Robotic Surgical System include the peripheral interventional radiology, interventional cardiology and interventional neuroradiology markets. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Microbot Medical Inc (MBOT) is a good buy right now due to its recent revenue growth of over 100% in Q2 2026, indicating strong market demand for its LIBERTY system, and a current price of $1.04, which is significantly below the analyst price target of $4. However, the company has a high net loss of $5,627,000 in Q2 2026, which poses a risk to its financial stability.

1 analysts cover MBOT: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 8.75.